These results suggest that circPDK1 is a promising biomarker for predicting PTX response and that the circPDK1/miR-4731-5p/GIGYF1 axis may be a therapeutic target for NSCLC. The gene discussed is GIGYF1; the disease is non-small cell lung carcinoma.